Risultati per: Come si esegue la raccolta delle urine delle 24 ore

Compie 25 anni la Giornata nazionale di Raccolta del Farmaco

Stroke, Volume 56, Issue Suppl_1, Page ATMP25-ATMP25, February 1, 2025. Introduction:Glial fibrillary acidic protein (GFAP), highly brain-specific, is emerging as an attractive blood biomarker in acute stroke. GFAP can discriminate stroke type (ischemic stroke (IS), intracerebral hemorrhage (ICH), stroke mimics (SM) in the first hours after stroke onset. Rapid GFAP levels using novel point-of-care technology (results

Stroke, Volume 56, Issue Suppl_1, Page ATMP73-ATMP73, February 1, 2025. Background:The therapeutic time window of endovascular therapy (EVT) for acute ischemic stroke (AIS) has been expanded up to 24 hours of onset. Patients with AIS beyond 24 hours may also benefit from EVT, but the actual status of this clinical issue is unknown.Purpose:To evaluate the real-world status of EVT for AIS beyond 24 hours of onset using a nation-wide stroke registry, Japan Stroke Data Bank (JSDB). JSDB is an ongoing hospital-based multicenter prospective registry of hospitalized patients with acute stroke or transient ischemic attack within 7 days of onset.Methods:From the JSDB dataset, patients with AIS who underwent EVT from 1996 through 2021 were analyzed. Patients were divided into 3 groups according to time from onset to hospital arrival (early: 24 hour). Outcomes included the favorable outcome (mRS 0–2 or return to pre-stroke mRS at discharge) and in-hospital mortality.Results:Among the 256,293 stroke patients, 91,907 AIS patients available for analysis were included in the present study. EVT was implemented in 6.9% (6,356/91,907) (median age 78 years; 41.6% women; median NIHSS score 16). The EVT rate by time window groups was 11.8% (4,258/36,044) for the early, 5.3% (1,676/31,328) for the late, and 1.7% (422/24,535) for the very late group. In the very late group with EVT, baseline NIHSS score was lowest (median 17 points in the early group, 14 points in the late group, and 5 points in the very late group), cardioembolism was least common (67.2%, 53.5%, and 22.0%, respectively), and large artery atherosclerosis was most common (17.9%, 30.8%, and 55.7%, respectively). Favorable outcome was more frequently achieved in the very late group (52.9%) than in the early (41.6%) and late (36.5%) groups. Symptomatic intracranial hemorrhage was more frequently seen in the very late group (6.0%) compared to the early (2.9%) and late (3.8%) groups, but in-hospital mortality was comparable among the time window groups (8.1% in the early group, 7.1% in the late group, and 6.6% in the very late group).Conclusions:Outcomes after EVT for patients with AIS beyond 24 hours were not necessarily worse than for patients with AIS up to 24 hours, but the patient profile in the very late group with EVT differed significantly from that in the early and late groups; developing optimal patient selection strategies for very late AIS may be required.

Stroke, Volume 56, Issue Suppl_1, Page A24-A24, February 1, 2025. Objectives:To investigate the correlation between iron deposition changes in the lesioned thalamic nuclei and the presence and severity of central post-stroke pain (CPSP) after thalamic infarction using quantitative susceptibility mapping (QSM) technique.Methods:We consecutively enrolled patients with unilateral chronic thalamic infarction with radiological examination conformed . Detailed and multidimensional pain characteristics measured as follows: Douleur Neuropathique 4 (DN4) questionnaire for validation of neuropathic pain diagnosis, Short-Form McGill Pain Questionnaire (SF-MPQ) for comprehensive representation of pain experience, Present Pain Intensity index (PPI) for current pain severity upon examination, and Visual Analogue Scale (VAS) for overall pain feeling since symptom onset. Age- and sex-matched stoke-free healthy controls were recruited simultaneously. High resolution structural image 3D-T1 BRAVO and QSM sequences were obtained with 3.0T MRI. The voxel-lesion-symptom-mapping (VLSM) was used to determine lesioned thalamic nuclei at the high risk for CPSP. Then ipsilateral QSM values of the whole thalamus and subregions were compared with contralateral side and healthy controls. Partial correlation analysis were performed to explore the relationship between QSM value and pain severity.Results:Finally, 28 CPSP patients, 33 non-CPSP patients and 55 healthy controls were included in the study. Our results indicated no significant difference in overall QSM values of the whole thalamus among the groups. The VLSM results showed lesion involving ventral posterolateral nuclei (VPL) was highly orrelaed with occurance of CPSP (pFWE=0.0092.). The QSM values of each subnuclei in the thalamus ipsilateral to infarction were lower compared with the contralateral side and healthy controls (p

Stroke, Volume 56, Issue Suppl_1, Page AWMP89-AWMP89, February 1, 2025. Introduction:Randomized clinical trials have demonstrated efficacy and safety of endovascular thrombectomy (EVT) among patients presenting up to 24 hours of last known well (LKW). Recent reports have suggested EVT could result in better functional outcomes with acceptable risk profile even in patients presenting beyond 24 hours of LKW, but exploration of the role of EVT in elderly patients presenting beyond 24 hours is limited.Methods:We aimed to evaluate functional and safety outcomes for EVT in patients with age ≥80y with a large vessel occlusion (LVO) beyond 24 hours of LKW, from a pooled, international cohort (17 centers across US, Spain, Australia and New Zealand) between 7/2012 and 12/2021. Primary outcome was a shift on modified Rankin Scale score at 90-day follow-up.Results:Of 301 included, 88 (53 EVT, 35 medical management MM) were aged ≥80y, with 57 females and 21 nonagenarians. Median(IQR) NIHSS – 17.5 (11-22),CT ASPECTS – 7(4-9), ischemic core 5.5 (0-26) ml. Overall, as age increased, clinical outcomes worsened (acOR: 0.64, 95% CI: 0.55-0.74, p

Stroke, Volume 56, Issue Suppl_1, Page A8-A8, February 1, 2025. Background:We investigate whether the NIHSS at 24 hours could serve as an alternative primary outcome measure in acute ischemic stroke trials, and whether combining 90-day modified Rankin Score (mRS) and 24-hour NIHSS in a hierarchical outcome could enhance detection of treatment effect, using EVT as an exemplary study intervention.Methods:Post-hoc analysis from the HERMES collaboration that pooled data from 7 randomized controlled EVT trials. Validity of 24-hour NIHSS as a surrogate outcome for 90-day mRS was assessed in a causal mediation model (Figure 1). A 7-point ordinal NIHSS score was generated by grouping 24-hour NIHSS, including death as a separate category (“ordinal” NIHSS). EVT effect sizes and sample sizes required for detecting EVT benefit with 80% power were compared when using granular 24-hour NIHSS, ordinal 24-hour NIHSS, 90-day mRS, and hierarchical outcome (win-ratio) that combines 90-day mRS and 24-hour NIHSS. Subgroup analyses were performed in patients with baseline NIHSS

Stroke, Volume 56, Issue Suppl_1, Page ATP21-ATP21, February 1, 2025. Introduction：The efficacy of blood pressure (BP) reduction of Sacubitril/valsartan has been proved in hypertension patients, yet not in patients with acute ischemic stroke (AIS). We aimed to investigate the efficacy and safety of Sacubitril/Valsartan in AIS patients with hypertension within 24-72 hours of symptom onset.Methods：Between November 2022 and May 2024, patients with AIS within 24-72h of symptom onset and BP≥140/90 mmHg were enrolled and randomly assigned to receive Sacubitril/Valsartan (100-200mg qd) or other antihypertensive medications determined by clinical physicians as the ratio of 1:1. Randomized antihypertensive treatment strategy was required to complied for 14 days, and allowed to be changed after day 14 if the BP control was not satisfied. All enrolled patients received other early medical managements based on the AIS guideline. The primary outcome was the proportion of participants who had a modified Rankin scale(mRS) score of 0-1 at 90 days. The secondary outcome was the rate of target BP control (mean BP

A eseguirli con successo l’equipe del professor Tomaso Bottio

Delicato intervento all’ospedale Cardarelli di Campobasso

Background
Children in paediatric emergency units are those who need special attention, and unless treated early, they are a vulnerable population to unwanted outcomes like death, discharge against medical advice or referral to other institutions within 24 hours.

Objectives
To assess admission outcomes and their associated factors among children admitted to the paediatric emergency unit of Dilla University Referral Hospital, Ethiopia, 2023.

Methods
An institution-based cross-sectional study design was employed among children admitted to the paediatric emergency unit at Dilla University Referral Hospital from 8 May 2023 to 8 June 2023. A total of 885 complete charts of the children aged 29 days to 14 years were analysed. Structured checklist was used for data collection. STATA V.14 was used for data analysis. A multinomial logistic regression model was used to determine the factors associated with admission outcomes. Overall model fitness was checked using the likelihood ratio test.

Result
Out of 885 patient charts reviewed, the magnitude of patients improved, transferred, died, referred and discharged against medical advice was 51%, 40.9%, 7.6%, 0.1% and 0.4%, respectively. Children presented with diarrhoea (adjusted OR (AOR) =2.92, 95% CI 1.46 to 5.84), severe respiratory distress (AOR=5.08, 95% CI 2.49 to 10.35), coma (AOR=3.71, 95% CI 1.24 to 11.13), comorbidity (AOR=3.33, 95% CI 1.49 to 7.41) and delay to seek healthcare (AOR=1.99, 95% CI 1.03 to 3.83) were significantly associated factors with emergency unit mortality, whereas pneumonia (AOR=1.76, 95% CI 1.16 to 2.65) and severe acute malnutrition (AOR=3.46, 95% CI 2.06 to 5.81) were significantly associated factors with intrahospital unit/ward transfer.

Conclusion
The magnitude of mortality, transfer to the ward and discharge against medical advice were relatively higher. Interventions focused on early diagnoses, and the initiation of appropriate treatments was of the utmost relevance to improving patient outcomes.

Musso, ‘grazie ai donatori. Passo verso autosufficienza Italia’

Introduction
Stress hyperglycaemia at hospital presentation is associated with poorer outcomes. Less is known about the risk of poorer outcomes according to achieved glycaemia early in the admission.

Research design/methods
This was a retrospective observational study of patients admitted to non-critical care wards. The aim was to determine the relationship between the day 2 peak blood glucose and the occurrence of hospital-acquired complications (HACs) or in-hospital mortality. A Cox proportional hazards model, adjusted for relevant covariates, was used to evaluate the impact of day 2 peak glucose on HACs and in-hospital mortality, and we identified peak glucose thresholds correlating with an increase in risk.

Results
For the whole cohort, day 2 peak glucose was associated with an increased risk of any HAC, aHR=1.06, 95% CI: 1.04, 1.07; but not in-hospital mortality, aHR=0.98, 95% CI: 0.94, 1.01. The risk of HAC infection increased by 4.6% for every mmol/L rise in day 2 peak glucose (aHR=1.05, 95% CI: 1.02, 1.08) in the diabetes cohort compared with 5.5% (aHR=1.06, 95% CI: 1.00, 1.11) in the non-diabetes cohort. The risk of HAC cardiac in the diabetes cohort increased by 5.3% (aHR=1.05, CI: 1.01, 1.10) per mmol/L increase in day 2 peak glucose; no association was found in the non-diabetes cohort (aHR=1.03, 95% CI: 0.94, 1.13). The risk for in-hospital mortality was associated with day 2 peak glucose, aHR=1.11, 95% CI: 1.03, 1.20, in patients without diabetes, but not in patients with diabetes, aHR=1.00, 95% CI: 0.95, 1.06. There was an increase in the risk of HAC once day 2 peak blood glucose exceeded 19.0 mmol/L (whole cohort), with thresholds of 13.6 mmol/L in the non-diabetes group and 19.5 mmol/L in the diabetes group.

Conclusion
The peak glucose on day 2 was a predictor of HAC in the entire cohort and in-hospital mortality in patients without diabetes.

In attesa di un posto letto in un ospedale del Salernitano

Objective
To evaluate the impact of Nurse-Family Partnership (NFP), a home-visiting programme, on exploratory maternal outcomes in British Columbia (BC), Canada.

Design
Pragmatic, parallel arm, randomised controlled trial conducted October 2013–November 2019. Random allocation of participants (1:1) to comparison (existing services) or NFP (plus existing services). Researchers were naïve to allocation.

Setting
26 local health areas across four of five BC regional health authorities.

Participants
739 young (

Analisi potrebbe individuare primissimi segni cellule cancerose

Stroke, Ahead of Print. BACKGROUND:Whether it is effective and safe to extend the time window of intravenous thrombolysis up to 24 hours after the last known well is unknown. We aimed to determine the efficacy and safety of tenecteplase in Chinese patients with acute ischemic stroke due to large/medium vessel occlusion within an extended time window.METHODS:Patients with ischemic stroke presenting 4.5 to 24 hours from the last known well, with a favorable penumbral profile and an associated large/medium vessel occlusion, were randomized 1:1 to either 0.25 mg/kg tenecteplase or the best medical treatment. A favorable penumbral profile was defined as a hypoperfusion lesion volume to infarct core volume ratio >1.2, with an absolute volume difference >10 mL, and an ischemic core volume 50% of the involved ischemic territory. Secondary outcomes included recanalization, infarct growth, major neurological improvements, change in the National Institutes of Health Stroke Scale score, hemorrhagic transformation within 24 to 48 hours, systemic bleeding at discharge, and modified Rankin Scale (score 0–1, score 0–2, score 5–6, and modified Rankin Scale distribution) at 90 days. The comparison of the primary outcome between groups was conducted using modified Poisson regression with a log-link function and robust error variance, adjusted for time from the last known well to randomization, the site of vessel occlusion, and planned endovascular treatment.RESULTS:Among 224 enrolled patients, 111 were assigned to receive tenecteplase and 113 to receive the best medical treatment (including 23% [n=26] of participants who received intravenous tissue-type plasminogen activator). The mean (SD) age of the tenecteplase group and the best medical treatment group was 64.2 (10.4) and 63.6 (11.0) years old, with 72.1% (n=80) and 70.8% (n=80) male enrolled, respectively. A proportion of 54.9% (n=123) of patients were transferred to the catheter room for preplanned endovascular treatment. The primary outcome occurred in 33.3% (n=37) of the tenecteplase group versus 10.8% (n=12) in the best medical treatment group (adjusted relative risk, 3.0 [95% CI, 1.6–5.7];P=0.001). Tenecteplase significantly increased the recanalization rate compared with the best medical treatment (35.8% [n=39] versus 14.3% [n=16], adjusted relative risk, 2.5 [95% CI, 1.4–4.4];P=0.002). There were no significant differences in clinical efficacy outcomes or rates of hemorrhagic transformation between the groups.CONCLUSIONS:Administered at a dose of 0.25 mg/kg intravenously, tenecteplase increased reperfusion without symptomatic intracranial hemorrhage in patients with ischemic stroke selected by imaging in late-time window treatment but did not change clinical outcomes at 90 days.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT04516993.